Skip to main content
      RT @MeralElRamahiMD: ➡️ASTERA = PIII trial that showed superior efficacy of Netakimab (IL-17Ai) vs PBO in pts w/ act

      Meral K. El Ramahi, MD MeralElRamahiMD

      4 years 5 months ago
      ➡️ASTERA = PIII trial that showed superior efficacy of Netakimab (IL-17Ai) vs PBO in pts w/ active r-axSpA. Excluded pts prev tx w/ 2 or more TNFi ➡️OP0142 = sub-analysis showing Netak ⬇️ dz activity in AS pts irrespective of sacroillitis on MRI at b/l #EULAR2021 @Rheumnow https://t.co/faT3M0xQiR
      RT @doctorRBC: I haven’t used it but… Netakimab (IL-17i) approved for treatment of PsO, AS, and PsA in Russia and Be

      Robert B Chao, MD doctorRBC

      4 years 5 months ago
      I haven’t used it but… Netakimab (IL-17i) approved for treatment of PsO, AS, and PsA in Russia and Belarus ⭐️⬇️AS activity w/ or w/o MRI sacroilitis Abs#OP0142 #EULAR2021 @RheumNow
      RT @KDAO2011: Bingo. It always had been rather odd to me that you would call someone nr-SpA when they had MR evidence of

      k dao KDAO2011

      4 years 5 months ago
      Bingo. It always had been rather odd to me that you would call someone nr-SpA when they had MR evidence of disease; xrays are not sensitive to pick up changes. While we're at it, can we just use the term "imaging" instead of "radiographs" with the availability of better tech? https://t.co/I6reoHyywf
      RT @doctorRBC: Filgotinib showed ⬇️ in spinal inflammation of AS pts after 12 weeks!
      ⭐️Subscores of the posterio

      Robert B Chao, MD doctorRBC

      4 years 5 months ago
      Filgotinib showed ⬇️ in spinal inflammation of AS pts after 12 weeks! ⭐️Subscores of the posterior elements, facet joints and vertebral bodies showed significant changes ⭐️no significant changes in spine fat, bone erosion or new bone formation Abs#OP0141 #EULAR2021 @RheumNow https://t.co/tcBFuxnu4n
      RT @doctorRBC: Fatigue 35-80% of rheumatic pts! Excellent talk on fatigue in arthritis, SpA and systemic rheumatic disea

      Robert B Chao, MD doctorRBC

      4 years 5 months ago
      Fatigue 35-80% of rheumatic pts! Excellent talk on fatigue in arthritis, SpA and systemic rheumatic disease! Abs#OP6875 #EULAR2021 @RheumNow How do you help pts manage fatigue?
      RT @MeralElRamahiMD: ➡️COMPLETE-AS = obs study of bDMARD-naive Canadians w/ active AS tx w/ ADA or nbDMARDS/NSAID.

      Meral K. El Ramahi, MD MeralElRamahiMD

      4 years 5 months ago
      ➡️COMPLETE-AS = obs study of bDMARD-naive Canadians w/ active AS tx w/ ADA or nbDMARDS/NSAID. ➡️> overall⬇️in dz burden & shorter time to achieve therapeutic response w/ ADA. But, ADA pts had higher b/l dz OP0143 #EULAR2021 @RheumNow https://t.co/FpJmugsdVw
      RT @doctorRBC: ⭐️All cancer excluding NMSC - 0.9HR TNFi vs cDMARD
      ⭐️Squamous cell CA - 1.2HR of TNFi vs cDMARD
      â

      Robert B Chao, MD doctorRBC

      4 years 5 months ago
      ⭐️All cancer excluding NMSC - 0.9HR TNFi vs cDMARD ⭐️Squamous cell CA - 1.2HR of TNFi vs cDMARD ⭐️No overall increase in all CA: RTX, TOCI ⭐️Abatacept 1.21HR for all cancer, mainly NMSC ⭐️needs more data on JAKs, IL-17, IL-23 Abs#6916 #EULAR2021 @RheumNow
      RT @MeralElRamahiMD: Efficacy & Safety of UPA after 1yr from SELECT-AXIS 1 study?

      ⭐️187 bDMARD-naive, active AS

      Meral K. El Ramahi, MD MeralElRamahiMD

      4 years 5 months ago
      Efficacy & Safety of UPA after 1yr from SELECT-AXIS 1 study? ⭐️187 bDMARD-naive, active AS pts w/ inadeq resp to NSAID ⭐️82-85% txed w/ UPA 15mg QD achieved BASDAI50 or ASDAS LDA over 64w 🚫 new safety signal & ZERO VTE, MACE, TB, or deaths w/ UPA. OP0144 #EULAR2021 @RheumNow https://t.co/mFbgQjsD6f
      RT @MeralElRamahiMD: ➡️5 cases of single-dermatome Herpes Zoster in 4 patients treated w/ UPA 15 mg QD for active AS

      Meral K. El Ramahi, MD MeralElRamahiMD

      4 years 5 months ago
      ➡️5 cases of single-dermatome Herpes Zoster in 4 patients treated w/ UPA 15 mg QD for active AS in SELECT-AXIS 1 ⭐️Do not forgot to vaccinate patients with 1st dose of Shingrix prior to starting a JAK-i. 2nd dose can be given after start of therapy OP0144 #EULAR2021 @RheumNow
      RT @MeralElRamahiMD: Do you vaccinate ALL patients (even if less than 50 yo) with first dose of Shingrix prior to starti

      Meral K. El Ramahi, MD MeralElRamahiMD

      4 years 5 months ago
      Do you vaccinate ALL patients (even if less than 50 yo) with first dose of Shingrix prior to starting a JAK-i? #EULAR2021. @RheumNow
      RT @Nellziade: Interesting results from our post hoc analysis of #ASAS #PerSpA presented at #EULAR2021 by Dafne Capelusn

      Nelly ZIADE 🍀 Nellziade

      4 years 5 months ago
      Interesting results from our post hoc analysis of #ASAS #PerSpA presented at #EULAR2021 by Dafne Capelusnik ⭐️Individual socioeconomic factors associated with poorer outcomes ⭐️Living in low GDP country associated with higher disease activity but paradoxically lower fatigue https://t.co/2SmKZPy8mw
      RT @acweyand: Congratulations to everyone who made it through the day today.

      Shematologist, MD acweyand

      4 years 5 months ago
      Congratulations to everyone who made it through the day today.
      RT @uptoTate: Poster #POS1033: Integrated analysis of 4 IXE SPIRIT trials
      IR for TEAEs ⬇️ over time
      IR for SAEs low

      Dr. Rachel Tate uptoTate

      4 years 5 months ago
      Poster #POS1033: Integrated analysis of 4 IXE SPIRIT trials IR for TEAEs ⬇️ over time IR for SAEs low serious infections/malignancies/MACE/IBD ⬇️ #EULAR2021 @RheumNow https://t.co/tLyXwnBDTo
      RT @uptoTate: GUS causes ⬇️ in serum collagen C1M (marker of joint response), C3M, C4M, C6M. Pts achieving ACR20 at

      Dr. Rachel Tate uptoTate

      4 years 5 months ago
      GUS causes ⬇️ in serum collagen C1M (marker of joint response), C3M, C4M, C6M. Pts achieving ACR20 at week 24 had greater C1M reduction than non-responder. Abstract #POS1036 #EULAR2021 @RheumNow https://t.co/4JqbaMexuR https://t.co/gXltKn6qIc
      RT @uptoTate: In biologic-naïve PsA pts - 2 yr data, GUS improved skin & joint symptoms, physical function, & r

      Dr. Rachel Tate uptoTate

      4 years 5 months ago
      In biologic-naïve PsA pts - 2 yr data, GUS improved skin & joint symptoms, physical function, & radiographic progression. Safety comparable to 6mo/1yr data, similar between Q4W & Q8W dosing, & consistent w/ PsO trials. Poster #POS1027 #EULAR2021 @RheumNow https://t.co/nlcjOX7cBq https://t.co/NWqDTwfb4u
      ×